Trial Profile
Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms DASFREE
- Sponsors Bristol-Myers Squibb
- 01 Sep 2023 Results of a five-year follow-up analysis (data lock: Dec 2021) published in the British Journal of Haematology
- 17 Jun 2022 Final 5-year results assessing TFR maintenance after dasatinib discontinuation, presented at the 27th Congress of the European Haematology Association
- 07 Dec 2021 Status changed from active, no longer recruiting to completed.